• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

N30 Pharmaceuticals

edit

N30 Pharma is a clinical‐stage company developing s‐nitrosothiol (SNO)‐based therapies for major unmet needs in respiratory, cardiovascular, and inflammatory diseases. N30 drugs target s‐nitrosoglutathione reductase (GSNOR), the only druggable enzyme that consumes s‐nitrosoglutathione (GSNO), a central regulator of the endogenous nitric oxide pool. GSNO, and other SNO’s are important modulators of inflammation as well as airway and vascular smooth muscle. N30 is a privately held company headquartered in Boulder, Colorado.

Milestones

edit

• 
  N30 Pharmaceuticals added Tom Sokolowski as CFO and VP Finance.
  Posted 7/12/10 at 5:03pm
• 
  N30 Pharmaceuticals added Charles Scoggin as CEO.
  Posted 7/12/10 at 5:03pm
• 
  N30 Pharmaceuticals received $10M in Series B funding. (7/12/10)
  Posted 7/12/10 at 5:03pm via onbiovc.com

Videos

Screenshots

edit

Sources

1. N30 Pharma, Inc.: Series B $10M (onbiovc.com) [edit]